| Name | Title | Contact Details |
|---|
Pharmexa-Epimmune Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Target RWE, we are redefining and revolutionizing the generation and delivery of real-world evidence. Contact us today!
Genomic Health, Inc. (NASDAQ: GHDX) is the world`s leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient`s journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.
Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic research, biotechnology, agriculture, medical diagnostics, and pharmaceutical development. The company`s primary business is the production of custom oligonucleotides for molecular biology applications. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, qPCR, and RNA interference. Through its GMP services, IDT manufactures products used in diagnostic tests for many forms of cancer and most inherited and infectious diseases. The company serves its customers through direct sales in many countries and a network of international distributors. IDT has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing facilities in San Diego, California, USA; Leuven, Belgium; and Singapore. The company has offices in Skokie, Illinois, USA; Glasgow, United Kingdom; Munich, Germany; and Baulkham Hills, Australia.
Minaris Regenerative Medicine is a global Contract Development and Manufacturing Organization (CDMO) with over 25 years of experience in cell and gene therapies. The company operates advanced facilities across North America, Europe, and Asia, providing comprehensive solutions for advanced therapy medicinal products (ATMPs). Minaris specializes in clinical and commercial manufacturing, process development, and technology transfer, ensuring compliance with regulatory standards in the U.S., EU, and Japan. The company offers a range of services, including GMP manufacturing for cell therapies, technology transfer, and clinical development support for Phase I-III trials. Minaris has successfully completed over 100 technology transfers and has recently commercialized LYFGENIA, a gene therapy for sickle cell disease. With a focus on collaboration, Minaris serves over 180 biotech and pharmaceutical clients, providing tailored solutions for their specific needs in regenerative medicine. Its facilities include expanded cleanroom capacity and analytical labs to support large-scale production.